SPPAM
MDGL icon

Summit Partners Public Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Summit Partners Public Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-82,287
Closed -$19M – 165
2023
Q4 		$19M Buy
+82,287
New +$14.4M 0.79% 48

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Summit Partners Public Asset Management's MDGL Position: Q1 2024 in Review

Summit Partners Public Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2024, closing a stake of 82,287 shares — an estimated $19M sold.

Summit Partners Public Asset Management first reported a position in MDGL in Q4 2023 and held it in 1 quarter. The position peaked at $19M in Q4 2023. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

  • Summit Partners Public Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 82,287 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $19M.
  • Summit Partners Public Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Summit Partners Public Asset Management's Madrigal Pharmaceuticals position peaked at $19M in Q4 2023.
  • 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on Summit Partners Public Asset Management's 13F filing for Q1 2024, filed 15 May 2024.